Committed to advancing productive and collaborative partnerships

      Our entrepreneurial, high-science culture in combination with our fast and nimble decision-making makes us the perfect partner for long-lasting and productive relationships.

      To maximize the value of our antibody platform AbiProt® and to build on our experience of eight approved and marketed drugs, we seek collaborations with other pharmaceutical and biotechnology companies to create or co-develop antibody products for novel disease targets.

      We are highly motivated to build strategic alliances that will help to improve patients’ lives by creating and developing innovative and differentiated antibody-based therapeutics.

      Our entrepreneurial, high-science culture in combination with our fast and nimble decision-making makes us the perfect partner for long-lasting and productive relationships.

      The growth engine of our partnerships is AbiProt® an antibody platform for scalable and cost-effective antibody development against highly important drug targets including historically “undruggable” targets.

      Our unique business model allows for three types of partnerships:

      Lead Generation

      • On-demand Lead Generation for selected targets.
      • Lead Generation of leads from our library of +275 disease-relevant antibody leads.

      R&D Collaboration

      • Technology partnerships and R&D / Discovery collaborations.

      Licensing

      • Licensing of our current pipeline of ten antibodies within oncology and pain.
      • Aiming at 10 new targets/year with 50% industry-sponsored portfolio.

      Current partnerships

      R&D collaboration / Licensing

      Top 20 Pharma Company
      A R&D collaboration with option to license for identification and verification of therapeutic antibody candidates against TRPV1.

      R&D collaboration

      Targovax
      Oblique Therapeutics AB (publ.) and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and Abiprot® technology platforms.
      ONCOS will be used to deliver Abiprot® antibodies against hard-to-reach targets such as mutant RAS.

      R&D collaboration

      Karolinska Institute
      Collaborations with Prof. Kent Jardemark at Translational pharmacology at the Department of Physiology and Pharmacology. Prof. Jardemark has expertise in antibody hit-to-lead screening, in vitro KRAS models, and ion-channel pharmacology.

      R&D collaboration

      Karolinska University Hospital
      Collaborations with Senior Physician Matthias Löhr at Department of Upper Gastroenterology, Karolinska Comprehensive Cancer Center. Clinical expertise in pancreatic cancer.

                            

      Partner with us!

      We are always open to discuss potential collaborations.
      Please contact us at: business_development@obliquet.com